Three settings, three different denominators
The paper asks how much RSV-associated acute respiratory infection (ARI) occurs among adults in high-income countries outside the hospital. It separates three settings that are easy to conflate. Community means all RSV cases in a population, whether or not people sought care, and eligible studies had to be prospective cohorts with active case ascertainment. Primary care means people who did seek care, split into outpatient or general practice and emergency department (ED) visits.
That distinction matters because each setting answers a different question. A community rate counts infections in a defined population over person-time. An outpatient or ED rate counts medically attended episodes per person-year. The RSV positive proportion is different again: it is the share of people tested for acute respiratory illness who test positive, a denominator of tested patients rather than of the whole population. The paper reports all three and does not treat them as interchangeable.
Six studies carry the incidence estimates
The systematic review searched six English-language databases for studies published between January 1996 and November 2024, registered in PROSPERO, and screened 5,800 records plus 329 from citation searching. Of 1,126 full texts assessed, 14 studies were included. Most were prospective (10 of 14) and from the US (10 of 14), and all confirmed RSV with nasopharyngeal specimens tested by PCR; one also used paired serology. All were rated high quality on Joanna Briggs Institute tools.
Only six of those studies contributed RSV incidence rates: two in the community, three in outpatients, and one in the ED. That small base is the main reason to read the age-specific numbers as estimates rather than settled values, and the authors graded ED incidence evidence as moderate because of wide confidence intervals, while community and outpatient incidence were graded high.
Correction factors roughly double the reported rates
A single respiratory specimen and a single diagnostic test can miss RSV, so raw study rates undercount cases. The authors applied correction factors to each study's reported incidence and positive-proportion estimates, accounting for the specimen type and test used. Across age groups and settings, the adjusted incidence rate was 2.0 to 2.3 times the unadjusted rate.
The correction is a modelling step, not a new measurement. Its underlying adjustment factors came from multi-specimen studies in hospitalised adults, because comparable multi-specimen studies in community or primary care were lacking. The authors note that pairwise comparisons using two specimens gave similar results by setting, and cite a community study in older adults where adding paired serology to nasopharyngeal RT-PCR raised RSV prevalence among ARI events 1.6-fold. Readers comparing this paper with uncorrected surveillance data should expect the gap to come largely from this step.
Community incidence barely differs by age
In the community setting, the adjusted RSV incidence rate was 6,104 per 100,000 person-years (95% CI 3,737–9,971) among adults aged 18–49, based on one study, and 5,311 per 100,000 person-years (95% CI 3,690–7,643) among those aged 50 and older, based on two studies with no observed between-study heterogeneity. The point estimate was slightly lower in the older group, and the confidence intervals overlap.
The authors read this flat pattern as a clue about what age changes. Because community studies actively ascertain cases regardless of care seeking, a lack of steep increase with age suggests age may matter more for RSV disease severity, and therefore for care seeking and hospitalisation, than for infection itself. They also raise the possibility that older adults have lower infection rates, citing a US community cohort showing declining RSV incidence with age above 50, and suggest changed contact behaviour or accumulated immunity as possible explanations, while stating that testing these hypotheses needs larger studies across the full age range.
Outpatient incidence climbs from 2,231 to 4,079
Among adults seeking outpatient care, the adjusted RSV incidence rate increased with age: 2,231 per 100,000 person-years (95% CI 1,088–4,577) at ages 18–49 from two studies, 3,113 (1,530–6,333) at ages 50–64 from two studies, and 4,079 (2,759–6,031) at ages 65 and older from three studies. Heterogeneity was zero in each pooled estimate.
The ED pattern was different in scale. Based on one study, adjusted incidence was 309 per 100,000 person-years (95% CI 142–676) at 18–49, 300 (98–919) at 50–64, and 685 (258–2,058) at 65 and older. Rates in the ED were substantially lower than in non-ED settings, and only the oldest group stood out. The paper's cross-setting comparison, which also draws on previously published hospitalisation estimates using the same correction approach, found the age-related rise was steepest in inpatient care, then ED, then outpatient, and flattest in the community.
Positive proportions cluster near 4 to 5 percent
Among adults with ARI who were tested, the adjusted RSV positive proportion was broadly similar across settings: 5.1% (95% CI 3.8–6.9) in the community from two studies, 3.7% (2.7–5.0) in outpatients from one study, and 4.3% (2.8–6.6) in the ED from one study. All three were substantially lower than the adjusted inpatient proportions of 10.4% at ages 18–64 and 16.5% at 65 and older reported in the paper's comparison table.
Older adults had a higher positive proportion in every setting: 13.7% (7.1–24.7) in the community and 10.7% (7.0–16.1) in outpatients at 65 and older. This is where the severity story becomes visible. A roughly stable share of tested ARI being RSV across community, outpatient, and ED contrasts with the much higher share among hospitalised patients, consistent with the authors' interpretation that age and setting track severity more than infection frequency.
Most community and outpatient RSV does not reach hospital
Six studies reported the share of RSV episodes that led to hospitalisation, and that share was substantially higher among outpatient cases than among community cases. The authors could not make meaningful age comparisons because confidence intervals were wide, reflecting few studies and small samples.
Deaths were rare in these settings. Across five studies reporting mortality among community or outpatient RSV cases in adults aged 50 and older, 60 and older, or 65 and older, no RSV deaths were reported among a total of 430 RSV episodes. In the ED, one study reported 2 deaths among 193 RSV cases, a case fatality rate of 1.0%. These counts describe the studied samples and should not be read as population-level fatality estimates.
The non-hospitalised burden dominates below 65
The paper's most decision-relevant comparison is a count, not a rate. Applying the adjusted rates to 2019 populations, the authors estimated 11.8 million outpatient RSV episodes annually in high-income countries at ages 18–49 and 7.5 million at ages 50–64, plus 1.6 million and 0.7 million ED episodes in those groups. Together that is roughly 21 million primary-care RSV episodes in adults under 65, which the authors describe as 50 times the estimated 0.4 million RSV-associated hospitalisations in the same age group.
That ratio is the paper's argument for looking beyond inpatient data when judging RSV vaccination impact, and the authors tie it to evidence that existing vaccines protect against RSV infections not requiring hospital admission. Two boundaries travel with the number. The authors state the total could be greater or lesser depending on how far data largely derived from the US apply to other high-income countries. And because only 17% to 31% of community RSV cases in older adults were medically attended, community incidence adds burden that never appears in clinic records. The practical priority is therefore the under-65 primary-care tier, where episode counts are largest, while the sharpest age gradient belongs to hospitalised and ED care.
Sources used in this answer
Respiratory syncytial virus disease burden among adults in community and primary care settings in high-income countries: a systematic review, meta-analysis, and modelling study
Adjusted RSV incidence was substantial in all adult age strata, with community rates similar at 18–49 and 50+ years, outpatient rates rising with age, and positive proportions of about 3.7–5.1% across community, outpatient, and ED settings.
